Type to search

European Commission Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss | Pharmtech Focus
FDA Accepts Supplemental Biologics License Application for Roche’s Polivy Combination for People With Previously Untreated Diffuse Large B-cell Lymphoma | Pharmtech Focus
CHMP Recommends EU Approval of Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss | Pharmtech Focus